Clinical Trials
15
Active:1
Completed:11
Trial Phases
4 Phases
Phase 1:4
Phase 2:3
Phase 3:4
+1 more phases
Drug Approvals
7
FDA:7
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (28.6%)Phase 3
4 (28.6%)Phase 2
3 (21.4%)Phase 4
3 (21.4%)Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users
Phase 4
Completed
- Conditions
- Abuse Potential
- Interventions
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Arbor Pharmaceuticals, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT06247488
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Overland Park, Kansas, United States
An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users
Phase 4
Completed
- Conditions
- Abuse Potential
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Arbor Pharmaceuticals, Inc.
- Target Recruit Count
- 86
- Registration Number
- NCT06097676
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Overland Park, Kansas, United States
Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
Phase 3
Completed
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Arbor Pharmaceuticals, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT03659929
- Locations
- 🇺🇸
114: Pharmacology Research Institute, Encino, California, United States
🇺🇸133: Collaborative Neuroscience Network, Garden Grove, California, United States
🇺🇸124: Pharmacology Research Institute, Newport Beach, California, United States
Relative Bioavailability of AR10 Compared to Reference Product
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2016-03-30
- Lead Sponsor
- Arbor Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02723669
Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry
Active, not recruiting
- Conditions
- CNS Tumor
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- Arbor Pharmaceuticals, Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT02684838
- Locations
- 🇺🇸
Spine and Neuro Center, Huntsville, Alabama, United States
🇺🇸Borrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸Spine Group Arizona At Honorhealth Scottsdale Osborn Medical Center, Scottdale, Arizona, United States
- Prev
- 1
- 2
- 3
- Next
News
No news found